IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto’s thyroiditis

Li-Tao Han†, Jia-Qian Hu†, Ben Ma, Duo Wen, Ting-Ting Zhang, Zhong-Wu Lu, Wen-Jun Wei, Yu-Long Wang, Yu WANG, Tian Liao* and Qing-Hai Ji *

Abstract

Background: The incidence of coexisting papillary thyroid cancer (PTC) and Hashimoto’s thyroiditis (HT) is increasing. The impact of HT on PTC prognosis and its possible mechanism remains controversial. Interleukin-17A (IL-17A) has been reported to participate in the pathogenesis of multiple autoimmune diseases and cancers. The aim of this study is to investigate the role of IL-17A in PTC with coexistent HT and evaluate the changes in tumor antigenicity.

Methods: Expression of IL-17A and major histocompatibility complex (MHC) class I molecules were compared on PTC tissue samples with or without HT. PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards. Cluster of differentiation (CD) 8⁺ T cell activation, production of Interleukin-2 (IL-2) and Interferon-gamma (IFN-γ) as well as the programmed death-1 (PD-1) expression on lymphocytes were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-17A pretreated PTC cells.

Results: Elevated IL-17A and MHC class I expression were observed in PTC tissue samples with coexistent HT. Stimulation of PTC cells with IL-17A effectively increased MHC class I expression in vitro. Coculture of PBLs with IL-17A pretreated PTC cells resulted in enhanced T cell activation (%CD25⁺ of CD3⁺ T cells) and increased IL-2 production along with decreased IFN-γ secretion and PD-1 expression of the lymphocytes.

Conclusions: Papillary thyroid cancer with coexisting Hashimoto’s thyroiditis presents elevated MHC class I expression, which may be the result of IL-17A secretion. T cell activation is enhanced in vitro by IL-17A and may provide future utility in PTC immunotherapy.

Keywords: Papillary thyroid cancer, Hashimoto’s thyroiditis, Immune escape, MHC class I molecule, Interleukin-17A, PD-1/PD-L1

Background

The incidence of papillary thyroid cancer (PTC) increases continuously over the last few decades, making PTC the fastest-growing cancer in most areas of the world [1]. In the meanwhile, Hashimoto’s thyroiditis (HT) is being frequently observed in PTC patients [2–4]. Extensive attention has been paid to PTC and coexistent HT to elucidate their association. Most of these studies argued patients with HT are more likely to have favorable prognosis, including one study completed at our institute [2, 5, 6]. However, contradictory views also exist [7, 8].

Multiple cytokines are involved in HT pathogenesis and they can consequently affect the course of the disease [9]. According to previous researches, cytokines are decisive regarding tumor growth and metastasis in various cancers, including PTC [10, 11]. Of special interest is interleukin 17A (IL-17A), whose expression is reported to be elevated in autoimmune diseases [12, 13].
Moreover, there were evidences linking IL-17A to cancerogenesis through immune activation in lung cancer and human papillomavirus (HPV) related epithelial cancers [14, 15]. In PTC and coexistent HT, the role of IL-17A remains undefined.

Major histocompatibility complex (MHC) class I molecules present endogenously derived peptides and elicit cytotoxic T lymphocytes (CTL), which is a crucial step in T-cell mediated antitumor immune response. However, tumor cells often downregulate MHC class I expression to achieve immune escape [16, 17]. Novel immunotherapy approaches are being explored to restore MHC class I expression. In this paper, we concentrate on lymphocyte infiltration. Because it is both the foundation for CTL killing and pathologic characteristic of HT. Studies have proved that enhanced CTL could augment immunotherapy [18]. Therefore, we hypothesized that HT alters MHC class I expression in PTC, which consequently changes patient outcome.

The aim of this study is to determine the role of IL-17A in PTC patients with coexistent HT, evaluate the changes in PTC immune antigenicity afterwards and investigate possible underlying mechanism.

Methods

Patients and tissue samples

PTC patients received radical surgery between Apr. 2014 and Jan. 2016 at the department of Head and Neck Surgery, Fudan University Shanghai Cancer Center were recruited in this study. Patients met the following criteria were included: 1) Pathologically confirmed to have primary PTC with or without the coexistence of HT; 2) No evidence of immunodeficiency; 3) No previous history of any treatment for thyroid conditions. Altogether, 138 patients were included in this study. Fresh-frozen thyroid specimens were obtained from 66 patients, while paraffin embedded tissue sections of the other 72 were acquired from the hospital tissue bank.

Tumorous (T) and adjacent para-tumor (PT) tissue were harvested from each patient. Clinical data (sex, age, tumor size, extrathyroidal invasion, metastasis, multifocality and TNM stage) were collected. TNM stage was decided according to the 8th edition of AJCC/UICC TNM staging system. Informed consent was obtained from all patients before research. The current study acquired Institutional Review Board approval from Fudan University Shanghai Cancer Center.

Cell lines and culture

Two PTC cell lines (K1 and TPC-1) and one normal human thyroid cell line Nthy-ori 3–1 were used in this study. K1 and TPC-1 were purchased from University of Colorado Cancer Center Cell Bank. Nthy-ori 3–1 was purchased from Sigma-Aldrich, Inc. All cell lines were cultured in RPMI 1640 medium containing 10% FBS (Invitrogen, Carlsbad, CA, USA) at 37°C with 5% CO₂ in proper humidity.

RNA extraction, reverse transcription and quantitative real time PCR (qPCR)

Total RNA of cultured cells and fresh frozen tissue samples was extracted with TRIzol Reagent (Invitrogen, Inc.) . 1μg total RNA was used as template for cDNA synthesis by means of a PrimeScript™ RT Reagent Kit (Takara, Dalian, China). Quantitative PCR was performed in triplicate using SYBR Green Premix Ex Taq™ II (Takara, Dalian, China). Expression of IL-17A, human leukocyte antigen (HLA) -A, HLA-B and HLA-C was then tested and β-actin was used as an internal control. Comparative cycle threshold values (2 -ΔΔCt) were adopted in analysis. Primer sequences are listed in Additional file 1: Table S1.

Immunohistochemistry (IHC)

Formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated with ethanol. Slices were treated with 3% H₂O₂ followed by heat-induced antigen retrieval (0.01 mol/L citrate, pH 6.0). 5% BSA was used to block non-specific protein-protein interactions. Sections were incubated overnight at 4°C with primary antibodies against IL-17A (Invitrogen, Carlsbad, CA, USA) at 1:1000 dilution. After the incubation, sections were counterstained with hematoxylin, dehydrated, and mounted with resin. Images were obtained through an Olympus IX71 inverted microscope with a DP2-BSW Olympus image acquisition software system. The sections were read separately by two experienced pathologists blinded to patient information and scored based on the extent of staining (0, no staining; 1, ≤10%; 2, 10–50%; and 3, >50%) as well as the intensity of staining (0, negative; 1, weak; 2, moderate; and 3, strong). These two scores were multiplied to generate an immunoreactivity score (IS) for each case.

Isolation of peripheral blood lymphocytes (PBLs)

Peripheral blood of healthy volunteers was drawn and placed onto human lymphocyte separation medium (Dakewe Biotech Co., Ltd). PBLs were isolated by differential density gradient centrifugation and plated in U-shaped bottom 96-well cell culture plates (2 x 10⁵ cells/well) using RPMI 1640 medium containing 10% FBS (Invitrogen, Carlsbad, CA, USA). Antibodies against CD3 (16–0037-85, eBioscience) and CD28 (16–0289-85, eBioscience) were added into each well (2 μg/mL). After 72 h, PBLs were dyed with fluorescence-conjugated antibodies against CD3 (300,308, BioLegend), CD8 (300,906, BioLegend) and CD25 (302,610, BioLegend) and sorted...
by flow cytometer (MoFlo XDP, Beckman Coulter, Inc.). Activated T cells (CD3^+CD8^+CD25^+) were collected.

**Pretreatment of PTC cell lines with IL-17A**

0.1 μg/μL of recombinant human IL-17A (200–17, Peprotech) was added in the culture media of K1 and TPC-1 cells for 24 h. all cells were washed thoroughly before further treatment.

**Coculture system of activated T cells and PTC cell lines**

Activated CD3^+CD8^+CD25^+T cells (1 × 10^5 cells/well, effector cells, E) were plated in wells with PTC cells (target cells, T) at an E:T ratio of 10:1 and 30:1 for 24 h.

**Flow cytometry**

Cells were transferred into centrifuge tubes and dyed with fluorescence-conjugated antibodies against MHC class I ABC (ab70328, Abcam), CD3 (300,308, BioLegend), CD25 (302,610, BioLegend) and PD-1 (329,918, Biolegend). After incubation, flow cytometry was performed using a Cytomics™ FC 500 cytometer (Beckman Coulter, Inc.). For the detection of MHC class I, cells were also stained with FITC-labeled goat anti-mouse secondary antibody (555,988, BD Pharmingen). Results were analyzed using FlowJo software (Tree Star).

**Enzyme-linked immunosorbent assay (ELISA)**

The supernatant fluid of the cocultured system was analyzed for IL-2 and IFN-γ concentration using precoated Human IL-2 ELISA Kit (12–1020-096, Dakewe Biotech Co., Ltd) and IFN-γ ELISA Kit (12–1000-096, Dakewe Biotech Co., Ltd). Briefly, samples and pre-diluted standards were added to precoated wells, followed by the detection antibody. After incubation, HRP conjugate and 3,3′,5,5′-tetramethyl benzidine dihydrochloride (TMB) was added to develop the plate. Absorbance of each well was read at 450 nm by Synergy H4 Hybrid microplate reader (BioTek).

**Western blot analysis**

Cell lysates were obtained with a mixture of RIPA protein extraction reagent, protease inhibitor and phosphatase inhibitor (Roche, CA, USA). Fresh frozen tissue samples were treated with T-PER™ Tissue Protein Extraction Reagent (Thermo Scientific®). Protein concentration was measured using a bichinchoninic acid assay (BCA). Protein lysate were then separated by 10% SDS-PAGE and transferred onto PVDF membranes, which were blocked in 5% non-fat milk and probed with primary antibodies against MHC class I (1:1000, Abcam) and GAPDH (1:5000, Abcam) at 4 °C overnight. After incubation in a solution of goat anti-rabbit or anti-mouse IgG (1:5000 for both; Jackson ImmunoResearch Laboratories), membranes were treated with enhanced chemiluminescence reagents (Thermo Fisher Scientific) and detected with Alpha Imager (Alpha Innotech, San Leandro, CA, USA).

**Statistical analysis**

All data are shown as mean ± SD or SEM as indicated. Independent t-tests were used for continuous variables and Pearson’s χ² tests were used for categorical variables. P < 0.05 was considered to indicate a statistically significant difference. Statistical tests were performed using GraphPad Prism 5.01 software (GraphPad Software, Inc.) and IBM SPSS 22.0 (Armonk, NY, USA). Graphs and figures were produced using GraphPad and Adobe Photoshop (Adobe Systems Inc.).

**Results**

**Patient characteristics**

A total number of 138 patients were included in this study. 110 (79.7%) of them were female. The majority of the cohort was under 55 yrs. (116, 84.1%). Over half of them (74, 53.5%) had microcarcinoma. Multifocal lesions

| Table 1 Clinical characteristics of all patients in this study (n = 138) |
|---------------------------------------------------------------|
| Clinicopathologic parameters | PTC | PTC + HT | p-value |
| Gender | | | | 0.000*** |
| Male | 26 | 2 | |
| Female | 63 | 47 | |
| Age (years) | | | | 0.272 |
| Mean | 42.3 ± 12.3 | 39.9 ± 12.5 | |
| < 55 | 73 | 43 | |
| ≥ 55 | 16 | 6 | |
| Tumor size (cm) | | | | 0.330 |
| Mean | 1.2 ± 0.7 | 1.3 ± 0.9 | |
| ≤ 1 | 52 | 22 | |
| > 1 | 37 | 27 | |
| Multifocal lesions | | | | 0.040* |
| Positive | 23 | 21 | |
| Negative | 66 | 28 | |
| Extrathyroidal invasion | | | | 0.339 |
| Positive | 8 | 7 | |
| Negative | 81 | 42 | |
| Lymph node metastasis | | | | 0.625 |
| Positive | 47 | 28 | |
| Negative | 42 | 21 | |
| TNM stage 8th | | | | 0.254 |
| I, II | 88 | 47 | |
| III, IV | 1 | 2 | |

*p < 0.05; ***p < 0.001

PTC papillary thyroid cancer, HT Hashimoto's thyroiditis
were found in 44 (31.9%) patients and extrathyroidal invasion was only positive in 15 (10.9%) patients. Lymph node metastasis occurred in 75 (54.3%) cases. According to the 8th edition of AJCC/UICC TNM staging criteria, only 3 (2%) patients was classified as stage III or IV.

The patient cohort was further divided by the diagnosis of coexistent HT. Postoperative pathology reports identified 49 (35.5%) cases of PTC + HT. The majority of them were female, with a higher proportion than that of PTC (95.9% vs. 70.8%, \(P < 0.001\)). Age, tumor size, extrathyroidal invasion, lymph node metastasis and TNM staging between these 2 groups showed no significant difference. However, our data revealed that patients with coexistent HT were more vulnerable to multifocal lesions (42.9% vs 25.8%, \(P = 0.040\)). Clinical characteristics of all 138 patients were listed in Table 1.

**Coexistent HT increases IL-17A expression in PTC**

Expression of IL-17A was examined in fresh frozen tissue samples from 66 PTC patients using qPCR. Among these patients, 35 (53%) had coexistent HT. A significantly higher expression of IL-17A in tumor tissues of PTC patients with coexistent HT was identified (\(P < 0.05\), Fig. 1a). Patients with PTC + HT were then divided by their level of IL-17A expression. Notably, more patients in IL-17A low expression group had lymph node metastasis than IL-17A high expression group (73.3% vs 35%, \(P = 0.025\)). Clinical characteristics of 35 PTC + HT patients in qPCR were listed in Table 2.

IHC staining of IL-17A was performed on paraffin embedded tissue sections from 72 patients. Results in Fig. 1b-c showed increased IL-17A expression on tumor...
tissue from PTC + HT, which was consistent with qPCR analysis. The results of adjacent para-tumor tissues from PTC and PTC + HT were not conclusive, for lack of enough positive cells on the section. Abundant infiltration of lymphocytes can be observed on sections of PTC + HT, indicating the pathologic characteristic of HT.

Coexistent HT increases MHC class I expression in PTC
Paraffin embedded tissue sections were tested for MHC class I expression by IHC staining. Patients with coexistent HT possessed higher MHC class I expression in both tumor and adjacent para-tumor tissues (Fig. 2a-b). No difference between tumor and adjacent para-tumor tissue in PTC. However, result of PTC + HT patient showed no clear distinction.

HLA-A, HLA-B and HLA-C expression were further tested by qPCR. An increased HLA-A expression was identified in tumor samples from patients with coexistent HT ($P < 0.01$, Fig. 2d). Statistical analysis of HLA-B and HLA-C expression failed to find differences between the two groups.

**IL-17A increases MHC class I expression in PTC cells in vitro**
To investigate the possible relationship between IL-17A and MHC class I expression in PTC, the baseline expression of MHC class I in all three cell lines was measured by flow cytometry. Compared with Nthy-ori 3–1, both K1 and TPC-1 had significantly lower mean fluorescence intensity (MFI) of MHC class I ($P < 0.05$, Fig. 3a). Cells of K1 and TPC-1 were then treated with 0.1 μg/μL recombinant human IL-17A for 24 h. As shown in Fig. 3b, IL-17A stimulation successfully increased MHC class I expression in both K1 and TPC-1 cells ($P < 0.05$).

**Effect of IL-17A stimulation on T cell activation in cocultures of CD3+CD8+CD25+T cells and PTC cell lines**
Coculture systems of T cells and PTC cell lines were adopted to determine the effect of IL-17A stimulation on T cells in vitro. Activated CD3+CD8+CD25+T cells were seeded along with IL-17A (0.1 μg/μL) stimulated K1 and TPC-1 cells at a ratio of effector cells (E, T cells) to targeted cells (T, PTC cells) of 10:1 or 30:1. After IL-17A pretreatment, significantly increased proportion of CD25+ cells of all CD3+T cells in coculture systems was detected by flow cytometry, regardless of specific PTC cell line or E:T ratio (Fig. 4a).

After 24 h of coculturing with pretreated PTC cells, the IL-2 secretion of T cells were dramatically increased compared with control groups, as was tested by ELISA. Significance was detected in both cell lines and at both ratios (Fig. 4b). IFN-γ production of coculture systems was further examined by ELISA. When the E:T ratio was set at 30:1, significantly reduced IFN-γ production was observed in cocultures of IL-17A stimulated PTC cells ($P < 0.001$, Fig. 4c). The amount of IFN-γ production in coculture systems differed greatly depend on the specific PTC cell line. Data showed the T cells in TPC-1 coculture systems exhibited higher capacity of IFN-γ production, over 10 times higher than that of K1 coculture systems.

Increased T cell activation further inspired us to investigate PD-1 expression. Flow cytometry result showed that activated CD3+CD8+CD25+T cells cocultured with IL-17A pretreated K1 cells presented reduced MFI of PD-1 at a E:T ratio of 30:1 ($P < 0.05$, Fig. 4d). However, no significant difference was found in TPC-1 coculture systems.

### Table 2 Clinical characteristics of PTC + HT patients in the qPCR cohort ($n = 35$)

| Clinicopathologic parameters | IL-17A Low | IL-17A High | $p$-value |
|-----------------------------|------------|-------------|-----------|
| Gender                      |            |             | 0.380     |
| Male                        | 0          | 1           |           |
| Female                      | 15         | 19          |           |
| Age (years)                 |            |             |           |
| Mean                        | 43.2 ± 12.0| 41.1 ± 13.9 | 0.642     |
| < 55                        | 13         | 17          | 0.889     |
| ≥ 55                        | 2          | 3           |           |
| Tumor size (cm)             |            |             |           |
| Mean                        | 1.1 ± 0.8  | 1.1 ± 0.4   | 0.761     |
| ≤ 1                         | 5          | 9           | 0.486     |
| > 1                         | 10         | 11          |           |
| Multifocal lesions          |            |             | 0.278     |
| Positive                    | 8          | 7           |           |
| Negative                    | 7          | 13          |           |
| Extrathyroidal invasion     |            |             | 0.195     |
| Positive                    | 4          | 2           |           |
| Negative                    | 11         | 18          |           |
| Lymph node metastasis       |            |             | 0.025*    |
| Positive                    | 11         | 7           |           |
| Negative                    | 4          | 13          |           |
| TNM stage 8th               |            |             | 0.093     |
| I, II                       | 13         | 20          |           |
| III, IV                     | 2          | 0           |           |

*$p < 0.05$  
PTC papillary thyroid cancer, HT Hashimoto’s thyroiditis
Discussion

In the current study, we identified an elevated expression of IL-17A in PTC with coexisting HT. Administration of IL-17A could effectively induce MHC class I expression in K1 and TPC-1 cells in vitro, which led to increased T cell activation and IL-2 production by PBLs cocultured with IL-17A pretreated PTC cell lines. Downregulation of IFN-γ and PD-1 was also observed along with T cell activation. Combined together, our study showed IL-17A enhanced T cell
activation in PTC with coexistent HT, possibly through PD-L1/PD-1 pathway.

The coexistence of HT and PTC has continuously drawing interests since Dailey et al. first reported the phenomenon [19]. A previous work of our institution found the presence of HT was a protective factor for central compartment lymph node metastasis in PTC [20]. Actually, the current study did not come to the same conclusion. This may due to our small sample size. Notably, our data showed PTC patients with HT were more vulnerable to multifocal lesions, a recognized risk factor for worse prognosis [21]. Even identified with risk factors, there were no differences as to the TNM stage between two groups, suggesting HT might be a protective factor. Yet this conclusion needs to be further validated by studies with a larger scale of patients.

HT triggers immune response specific to thyroid, leading to lymphocyte infiltration, cytokine production and the destruction of normal thyroid tissue [9]. Former researchers have established that IL-17A, which is a pro-inflammatory cytokine in autoimmune diseases, could also participates in tumor development [12–15]. In breast cancer, elevated IL-17A expression results in polarization of neutrophils which suppress CTLs and eventually, promoting metastases [22]. Gomes et.al. showed blocking IL-17A axis prevents hepatocellular carcinoma [23]. Although its role in cancer has been widely described as pro-tumorous, there also exist studies proving the antitumor effect of IL-17A. Injecting recombinant Lactococcus lactis strain secreting IL-17A into a mouse allograft model of HPV-induced cancer effectively prolonged the disease free survival in contrast to control mice treated with the wild type strain of L. lactis [24]. In PTC, an analysis of Korean population revealed IL-17A SNP rs2275913 was significantly associated with lack of multifocality [25]. Considering that rs2275913 is a promoter SNP in IL-17A, their results strongly suggest the role of IL-17A in the cancerogenesis
of PTC. The underlying mechanism needs to be further investigated. To our best knowledge, this is the first study to evaluate IL-17A in the context of coexisting PTC and HT. We hypothesized that IL-17A expression would be elevated in PTC + HT because of coexistent HT. Our results came confirmative. More interestingly was that the clinical data showed patients with high IL-17A expression had less lymph node metastasis, indicating its protective function in PTC.

Loss of MHC class I expression is a frequent mechanism of immune escape in PTC [17]. Restoration of MHC class I has been proved to be a promising mechanism to enhance immunotherapy efficacy in melanoma, hepatocellular carcinoma and other malignancies [26, 27]. In the current study, an increased expression of MHC class
I was detected in PTC patients with HT, indicating suppressed immune escape in these patients. IL-17A expression was reported to elevate in Treg-decreased patients with unresectable pancreatic cancer after chemotherapy, suggesting its role in immune escape [28]. By in vitro administration of IL-17A, we successfully proved that MHC class I expression was induced in PTC cell lines (K-1 and TPC-1). Elevated expression of MHC class I could strengthen T cell mediated cytotoxicity. In the current study, increased CD25+% within CD3+T cells and IL-2 secretion were observed in cocultures of isolated PBLs and IL-17A stimulated PTC cells, indicating IL-17A induced MHC class I expression was accompanied by increased antigenicity in PTC.

IFN-γ production by the PBLs cocultured with pre-treated PTC cells were downregulated in our study. IFN-γ is widely thought to be a representative antitumor cytokine, however it also has been proved to induce PD-L1 expression and impair tumor immunity [29]. Activation of costimulatory molecules programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) facilities immune escape in multiple malignancies including PTC [30, 31]. Our data showed downregulation of IFN-γ was accompanied by decreased PD-1 expression, suggesting the immune escape suppressed by IL-17A may be linked to PD-1/PD-L1 pathway.

There are also unanswered questions and limitations in the present study. A major flaw is that our findings of IL-17A, which were interesting and may provide new insights in immune therapy, could not fully represent HT. The role of PD-1/PD-L1 pathway in PTC and coexistent HT has not been thoroughly examined. Statistical analysis of clinical data may also be compromised by the small sample size. Future researchers need to take circulating cytokines into consideration as well.

Conclusions
We successfully demonstrated IL-17A induced MHC class I expression and promotes tumor antigenicity in PTC, and may be related to PD-1/PD-L1 pathway. This result may facilitate immunotherapy in cancers with downregulated MHC class I expression.

Additional file

Additional file 1: Table S1. Primer sequences of target genes for qPCR.

Abbreviations
CD: Cluster of differentiation; CTL: Cytotoxic T lymphocytes; HLA: Human leukocyte antigen; HPV: Human papillomavirus; HT: Hashimoto’s thyroiditis; IFN-γ: Interferon-gamma; IL-17A: Interleukin-17A; IL-2: Interleukin-2; MHC: Major histocompatibility complex; PBL: Peripheral blood lymphocytes; PD-1: Programmed death-1; PTC: Papillary thyroid cancer

Acknowledgements
Not applicable

Authors’ contributions
Conception and design: TLIAO, QHJ, JQHJ, YWANG. Acquisition of clinical data: LTHAN, JQ, HU, D WEN, TTZHANG. Conduction of experiments: LTHAN, B MA, JQ, HU. Analysis and interpretation of data: LTHAN, JQ, HU, ZW, LU, WJ, WEL, YL, WANG. Writing of the manuscript: TLIAO, JQ, HU, LTHAN. Administrative and material support: YL WANG, WJ WEI. Study supervision: TLIAO, QH, JI. All authors read and approved the final manuscript.

Funding
This work was partly supported by grants from the National Natural Science Foundation of China (81772854, 81722622 to Qing-Hai JI, and 81702753 to Tian LIAO), the Shanghai Health Planning Commission Project (20164014730 to Yu WANG), the Shanghai Shenkang Suitable Technology Joint Development and Application Project (SHDC12016208 to Yu WANG) and the Science and Technology Commission of Shanghai Municipality (16411966700 to Yu WANG).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its additional file.

Ethics approval and consent to participate
Informed consent was obtained from all patients before research. The current study acquired Institutional Review Board approval from Fudan University Shanghai Cancer Center.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 24 February 2019 Accepted: 23 May 2019
Published online: 04 June 2019

References
1. La VC, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9): 2187–95.
2. Qu N, Zhang L, D-z L, Ji QH, Y-x Z, Wang Y. The impact of coexistent Hashimoto’s thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma. Tumor Biol. 2016;37(6):7685–92.
3. Nam HY, Lee H, Park G. Impact of co-existent thyroiditis on clinical outcome in papillary thyroid carcinoma with high preoperative serum anti-thyroglobulin antibody: a retrospective cohort study. Clin Otolaryngol. 2016;41(4):358–64.
4. Catargeli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S. Hashimoto’s thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid. 2013;23(2):142–50.
5. Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital. 2017;37(5):393–400.
6. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, et al. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013;148(3):396–402.
7. Konturek A, Barczyński M, Wierchowska W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbeck’s Arch Surg. 2013;398(3):389–94.
8. Stanciu AE, Serdarevic N, Hurdac AE, Stanciu MM. IL-4, IL-10 and high sensitivity-IRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma without Hashimoto’s thyroiditis. Scand J Clin Lab Invest. 2015;75(7):539–48.
9. Figueroa-Vega N, Alfonso-Perez M, Benedico I, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. The Journal of Clinical Endocrinology & Metabolism. 2010;95(2):953–62.
10. Cho S, Kim Y, Sun H, Kim Y, Oh B, Yi K, et al. Cxcl16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma. Endocr Relat Cancer. 2016;23(2):113–24.

11. Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, et al. Role of IL-6-mediated expression of Ns5a in autophagy of liver cancer cells. J Cell Physiol. 2018;233(12):9312–9319.

12. Seo K, Kitamura K, Han S, Kelsall B. T17 cells mediate inflammation in a novel model of spontaneous experimental autoimmune lachrymal keratoconjunctivitis with neural damage. J Allergy Clin Immunol. 2018;142(1):96–108 e2.

13. Fang S, Huang Y, Wang S, Zhang Y, Luo X, Liu L, et al. IL-17A exacerbates fibrosis by promoting the Proinflammatory and Profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab. 2016;101(8):2955–65.

14. Van Hede D, Polese B, Humbert C, Wilharm A, Renoux V, Dortu E, et al. Human papillomavirus oncoproteins induce a reorganization of epithelial-associated γδ T cells promoting tumor formation. Proc Natl Acad Sci U S A. 2017;114(43):E9056–E65.

15. Akbay E, Koyarna S, Liu Y, Dries R, Buie L, Silkes M, et al. Interleukin-17A promotes lung tumour progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol. 2017;12(8):1268–79.

16. Garrido F, Aptsiauri N, Doorduijn E, Garcia Lora A, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44–51.

17. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014;20(23):6034–44.

18. Barreira Da SR, Albert M. Dipeptidylpeptidase IV inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015;16(8):850–8.

19. Dalley ME, Lindsay S, Shahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA archives of surgery. 1955;70(2):291–7.

20. Zhang L, Li H, Ji Q-h, Y-x Z, Z-y W, Wang Y, et al. The clinical features of papillary thyroid cancer in Hashimoto’s thyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer. 2012;12(1):610.

21. Sessa L, Lombardi C, De Crea C, Tempera S, Bellantone R, Raffaelli M. Risk factors for central neck lymph node metastases in micro- versus macro-clinically node negative papillary thyroid carcinoma. World J Surg. 2018;42(3):623–9.

22. Coffelt SB, Kersten K, Doonanb OW, Weiden J, Wijland K, Hau C-S, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345.

23. Gomes Ana L, Teijeiro A, Baer A, Tummala Krishna S, Yilmaz M, Waisman A, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161–75.

24. Jacquoton E, Torres Maravilla E, Boucard A-S, Pouderous N, Pessoa Vilela AP, Nazzari I, et al. Anti-tumoral effects of recombinant Lactococcus lactis strain secreting IL-17A cytokine. Front Microbiol. 2019;10:3355.

25. Lee YC, Chung JH, Su KK, Sang YR, Chon S, Oh SJ, et al. Association between interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine. 2015;71(2):283–8.

26. Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, et al. Mutational analysis of pro- and antitumor immunity. Opin Immunol. 2016;39:44–51.

27. Zhang J, Xu Z, Zhou X, Zhang H, Yang N, Wu Y, et al. Loss of expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol. 2016;233(12):9312–9319.

28. Liu C, Cheng H, Luo G, Lu Y, Jin K, Guo M, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Int J Oncol. 2017;51(2):686–94.

29. Mandai M, Hamanishi J, Abiko K, Matsunaga N, Baba T, Konishi I. Dual faces of IFNγ in Cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22(10):2529–34.

30. Akbay EA, Koyarna S, Canetero J, Altafar A, Tschicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer discovery. 2013;3(12):1355–63.

31. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Kopper JP, et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):E934–E43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.